Quantbot Technologies LP Purchases Shares of 103,621 Option Care Health, Inc. (NASDAQ:OPCH)

Quantbot Technologies LP acquired a new stake in Option Care Health, Inc. (NASDAQ:OPCH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 103,621 shares of the company’s stock, valued at approximately $2,404,000.

Other hedge funds also recently made changes to their positions in the company. Westfield Capital Management Co. LP lifted its position in shares of Option Care Health by 10.2% in the third quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company’s stock valued at $203,204,000 after buying an additional 599,589 shares during the last quarter. Graypoint LLC acquired a new stake in shares of Option Care Health in the fourth quarter valued at approximately $1,161,000. Charles Schwab Investment Management Inc. lifted its position in shares of Option Care Health by 6.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,510,131 shares of the company’s stock valued at $58,235,000 after buying an additional 147,054 shares during the last quarter. Global Alpha Capital Management Ltd. lifted its position in shares of Option Care Health by 38.1% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 68,810 shares of the company’s stock valued at $1,596,000 after buying an additional 18,992 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Option Care Health in the fourth quarter valued at approximately $327,000. 98.05% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the firm’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $33.26, for a total transaction of $1,030,926.96. Following the transaction, the insider now owns 44,974 shares in the company, valued at $1,495,835.24. This trade represents a 40.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.64% of the company’s stock.

Option Care Health Price Performance

Option Care Health stock opened at $34.58 on Friday. The stock’s fifty day moving average price is $31.84 and its two-hundred day moving average price is $28.32. Option Care Health, Inc. has a one year low of $21.39 and a one year high of $34.85. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.73 and a quick ratio of 1.32. The firm has a market cap of $5.72 billion, a PE ratio of 29.06, a price-to-earnings-growth ratio of 2.30 and a beta of 1.33.

Wall Street Analysts Forecast Growth

OPCH has been the subject of a number of recent analyst reports. Barrington Research raised their price objective on Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. Bank of America raised Option Care Health from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $26.00 to $33.00 in a report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and set a $30.00 price target (down from $31.00) on shares of Option Care Health in a report on Friday, January 10th. JPMorgan Chase & Co. lifted their price target on Option Care Health from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Finally, UBS Group assumed coverage on Option Care Health in a report on Thursday, December 5th. They set a “neutral” rating and a $26.00 price target for the company. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.